UY31421A1 - Arilindenopirimidinas y su uso como adenosina a2a - Google Patents

Arilindenopirimidinas y su uso como adenosina a2a

Info

Publication number
UY31421A1
UY31421A1 UY31421A UY31421A UY31421A1 UY 31421 A1 UY31421 A1 UY 31421A1 UY 31421 A UY31421 A UY 31421A UY 31421 A UY31421 A UY 31421A UY 31421 A1 UY31421 A1 UY 31421A1
Authority
UY
Uruguay
Prior art keywords
arylindenopirimidins
adenosine
arylindenopyrimidines
prophylactic
disorders
Prior art date
Application number
UY31421A
Other languages
English (en)
Inventor
Paul F Jackson
Brian C Shook
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31421A1 publication Critical patent/UY31421A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a arilindenopirimidinas novedosas A,B y C y a sus terapéuticos y profilácticos. Los trastornos que se tratan o previenen utilizando estos compuestos incluyen la enfermedad de Parkinson.
UY31421A 2007-10-25 2008-10-24 Arilindenopirimidinas y su uso como adenosina a2a UY31421A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98245607P 2007-10-25 2007-10-25

Publications (1)

Publication Number Publication Date
UY31421A1 true UY31421A1 (es) 2009-04-30

Family

ID=40225283

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31421A UY31421A1 (es) 2007-10-25 2008-10-24 Arilindenopirimidinas y su uso como adenosina a2a

Country Status (13)

Country Link
US (1) US20090111804A1 (es)
EP (1) EP2220053B1 (es)
JP (1) JP2011500833A (es)
CN (1) CN101835760A (es)
AR (1) AR069026A1 (es)
AT (1) ATE509012T1 (es)
AU (1) AU2008316821A1 (es)
CL (1) CL2008003184A1 (es)
PA (1) PA8801401A1 (es)
PE (1) PE20091345A1 (es)
TW (1) TW200934496A (es)
UY (1) UY31421A1 (es)
WO (1) WO2009055548A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
ATE212635T1 (de) * 1997-12-05 2002-02-15 1,3,8-triazaspiro(4,5)decan-4-on-derivate
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
ES2326075T3 (es) * 2003-10-03 2009-09-30 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Arilidenopiridinas y arilidenopirimidinas y su uso como antagonistas del receptor de adenosina a2a.

Also Published As

Publication number Publication date
CN101835760A (zh) 2010-09-15
ATE509012T1 (de) 2011-05-15
PA8801401A1 (es) 2009-05-15
EP2220053A1 (en) 2010-08-25
US20090111804A1 (en) 2009-04-30
PE20091345A1 (es) 2009-09-24
EP2220053B1 (en) 2011-05-11
AU2008316821A1 (en) 2009-04-30
AR069026A1 (es) 2009-12-23
WO2009055548A1 (en) 2009-04-30
JP2011500833A (ja) 2011-01-06
CL2008003184A1 (es) 2009-10-16
TW200934496A (en) 2009-08-16

Similar Documents

Publication Publication Date Title
EA200900202A1 (ru) Селективные модуляторы андрогенного рецептора, их аналоги и производные и их использование
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
HN2006037713A (es) Compuestos utiles en terapia
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
BRPI0614397A2 (pt) compostos de pirimidina como moduladores de receptor de serotonina
UY30052A1 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
GT200600106A (es) Agentes endoparasiticidas
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
ECSP11010977A (es) Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas
UY31420A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina
UY31421A1 (es) Arilindenopirimidinas y su uso como adenosina a2a
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
ECSP12011842A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS
ECSP12011840A (es) Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos